CL2023000261A1 - Métodos de tratamiento de la neuralgia del trigémino - Google Patents

Métodos de tratamiento de la neuralgia del trigémino

Info

Publication number
CL2023000261A1
CL2023000261A1 CL2023000261A CL2023000261A CL2023000261A1 CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1 CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A CL2023000261 A CL 2023000261A CL 2023000261 A1 CL2023000261 A1 CL 2023000261A1
Authority
CL
Chile
Prior art keywords
trigeminal neuralgia
treatment methods
neuralgia treatment
subject
methods
Prior art date
Application number
CL2023000261A
Other languages
English (en)
Inventor
Garibaldi George
Original Assignee
Noema Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noema Pharma Ag filed Critical Noema Pharma Ag
Publication of CL2023000261A1 publication Critical patent/CL2023000261A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

En el presente documento se proporcionan métodos para tratar la neuralgia del trigémino en un sujeto que lo necesite mediante la administración al sujeto de composiciones que comprenden un modulador alostérico negativo (NAM) de mGlu5, que tiene la estructura de Fórmula (I).
CL2023000261A 2020-07-30 2023-01-26 Métodos de tratamiento de la neuralgia del trigémino CL2023000261A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063058630P 2020-07-30 2020-07-30

Publications (1)

Publication Number Publication Date
CL2023000261A1 true CL2023000261A1 (es) 2023-09-08

Family

ID=77520687

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000261A CL2023000261A1 (es) 2020-07-30 2023-01-26 Métodos de tratamiento de la neuralgia del trigémino

Country Status (14)

Country Link
US (1) US20230172922A1 (es)
EP (1) EP4188370A1 (es)
JP (1) JP2023540849A (es)
KR (1) KR20230047132A (es)
CN (1) CN115989024A (es)
AR (1) AR123108A1 (es)
AU (1) AU2021316675A1 (es)
BR (1) BR112023001621A2 (es)
CA (1) CA3182457A1 (es)
CL (1) CL2023000261A1 (es)
IL (1) IL300124A (es)
MX (1) MX2023001288A (es)
TW (1) TW202220649A (es)
WO (1) WO2022023519A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
PT1756086E (pt) * 2004-06-01 2008-08-08 Hoffmann La Roche Piridin-4-il-etinil-imidazoles e pirazoles como antagonistas dos receptores mglu5
RU2460728C2 (ru) * 2006-12-21 2012-09-10 Ф. Хоффманн-Ля Рош Аг Соль моносульфат 2-хлор-4-[1-(4-фторфенил)-2,5-диметил-1н-имидазол-4-илэтинил]-пиридина и ее кристаллическая форма, содержащая их фармацевтическая композиция и способ получения
US8211882B2 (en) * 2008-03-08 2012-07-03 Richard Delarey Wood Glutamate receptor modulators and therapeutic agents

Also Published As

Publication number Publication date
KR20230047132A (ko) 2023-04-06
JP2023540849A (ja) 2023-09-27
CN115989024A (zh) 2023-04-18
CA3182457A1 (en) 2022-02-03
TW202220649A (zh) 2022-06-01
IL300124A (en) 2023-03-01
AU2021316675A1 (en) 2023-01-19
BR112023001621A2 (pt) 2023-04-04
US20230172922A1 (en) 2023-06-08
AR123108A1 (es) 2022-10-26
WO2022023519A1 (en) 2022-02-03
EP4188370A1 (en) 2023-06-07
MX2023001288A (es) 2023-04-28

Similar Documents

Publication Publication Date Title
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2020004249A2 (es) Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
CL2017002693A1 (es) Métodos para tratar infecciones por el virus filoviridae. divisional de solicitud n° 1040-2017.
CO2020010552A2 (es) Compuestos
CO2020006523A2 (es) Compuestos moduladores de sting y métodos de elaboración y uso
ECSP21033236A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
CR20170595A (es) Piridinas sustituidas y método de uso
CO2020002959A2 (es) Moduladores de piruvato quinasas y uso de los mismos
BR112015022577A2 (pt) moduladores ship1 e métodos relacionados a esse
EA202191519A1 (ru) Модуляторы trex1
CO2022000481A2 (es) Inhibidores de enzimas
NI202000062A (es) Régimen posológico del modulador del ensamblaje de la cápside
AR108344A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORgT
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
CO2023004195A2 (es) Compuestos heterocíclicos
UY37706A (es) Compuestos antitumorales
CO2022014673A2 (es) Nuevos compuestos útiles para el tratamiento y/o prevención de una enfermedad, trastorno o afección asociada con la angiotensina ii
EA201891808A1 (ru) Трис-амидные соединения и композиции, содержащие их
ECSP20027220A (es) Mitoflavoscinas: la fijación como objetivo de enzimas que contienen flavina elimina células madre cancerosas (cscs) al inhibir la respiración mitocondrial
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
CO2024001256A2 (es) Compuesto inductor de la degradación de plk1 novedoso
CL2023003168A1 (es) Moduladores de trex1